Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/19 → 2/21/22 |
Funding
- Nektar Therapeutics: $114,398.00
A Phase 1/2, Open-label, Multicenter Study of the Combination of Nktr-214 and Nivolumab or the Combination of Nktr-214, Nivolumab, and Other Anti-cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
- Arnold, Susanne (PI)